Latest Tuberculosis Vaccine Trial Results Show Mixed Success
最新結核病疫苗試驗結果顯示成效不一
For over a century, the BCG vaccine has been the only tool against tuberculosis (TB).
一個多世紀以來，卡介苗（BCG）一直是對抗結核病（TB）的唯一工具。
Recent April 2026 Phase 3 trials in India evaluating VPM1002 and Immuvac highlight a complex, mixed landscape in vaccine research.
2026年4月在印度進行的評估VPM1002和Immuvac的第三期臨床試驗突顯了疫苗研究中複雜且參差不齊的現狀。
However, VPM1002 achieved a notable 50.4% efficacy against deadly extrapulmonary TB, and showed ~65% efficacy in children aged 6–14.
然而，VPM1002在對抗致命的肺外結核方面達到了顯著的50.4%防護效力，並且在6至14歲的兒童群體中展現了約65%的效力。
Meanwhile, the M72/AS01E vaccine remains the field's frontrunner.
與此同時，M72/AS01E疫苗依然是該領域的領先者。
Currently in Phase 3 trials, it previously demonstrated a promising 50% efficacy in preventing active TB in adults with latent infections.
它目前正處於第三期試驗，曾顯示在預防成年人潛伏性感染並進展為活動性結核方面具有50%的前景效力。
Instead of seeking a single 'holy grail' vaccine, researchers are moving toward precision immunization.
研究人員正在邁向精準免疫，而非追求單一的「聖杯」疫苗。
